CD19 and follicular lymphoma: Treating follicular lymphoma (FL) patients with anti-CD19 CAR-T cells in clinical practice is already possible, since axi-cel and tisa-cel recently received Food and Drug Administration (FDA) and European Medicine Agency (EMA) approval.